Genetic variation in FCER1A predicts peginterferon alfa-2a-induced hepatitis B surface antigen clearance in East Asian patients with chronic hepatitis B.
Adult
Alleles
Antiviral Agents
/ therapeutic use
Asian People
Drug Therapy, Combination
Female
Genetic Variation
Genome-Wide Association Study
Hepatitis B Surface Antigens
/ immunology
Hepatitis B, Chronic
/ drug therapy
Humans
Interferon-alpha
/ therapeutic use
Male
Microarray Analysis
Middle Aged
Polyethylene Glycols
/ therapeutic use
Polymorphism, Single Nucleotide
RNA Polymerase III
/ genetics
Receptors, IgE
/ genetics
Recombinant Proteins
/ therapeutic use
chronic hepatitis B
genetic variation
peginterferon alfa-2a
response
Journal
Journal of viral hepatitis
ISSN: 1365-2893
Titre abrégé: J Viral Hepat
Pays: England
ID NLM: 9435672
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
16
08
2018
revised:
06
02
2019
accepted:
14
03
2019
pubmed:
12
4
2019
medline:
25
7
2020
entrez:
12
4
2019
Statut:
ppublish
Résumé
In a multicentre, genome-wide association study to identify host genetic factors associated with treatment response in adult chronic hepatitis B patients, genotype data were obtained by microarray analysis from 1669 patients who received peginterferon alfa-2a for ≥ 24 weeks with/without a nucleos(t)ide analog. Treatment response was assessed at least 24 weeks post-treatment, using serological and/or virological endpoints. Thirty-six single-marker analyses and a gene-by-gene analysis were conducted. No single nucleotide polymorphisms (SNPs) achieved genome-wide significance (P < 5 × 10
Substances chimiques
Antiviral Agents
0
FCER1A protein, human
0
Hepatitis B Surface Antigens
0
Interferon-alpha
0
Receptors, IgE
0
Recombinant Proteins
0
Polyethylene Glycols
3WJQ0SDW1A
POLR3G protein, human
EC 2.7.7.-
RNA Polymerase III
EC 2.7.7.6
peginterferon alfa-2a
Q46947FE7K
Banques de données
ClinicalTrials.gov
['NCT01855997']
Types de publication
Clinical Trial, Phase IV
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1040-1049Informations de copyright
© 2019 John Wiley & Sons Ltd.
Références
World Health Organization (WHO). Hepatitis B fact sheet No 204. July 2015. Available at: http://who.int/mediacentre/factsheets/fs204_Jul2014/en/. Accessed May 21, 2018.
Dienstag JL. Hepatitis B virus infection. N Engl J Med. 2008;359:1486-1500.
Kamatani Y, Wattanapokayakit S, Ochi H, et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet. 2009;41:591-595.
Guo X, Zhang Y, Li J, et al. Strong influence of human leukocyte antigen (HLA)-DP gene variants on development of persistent chronic hepatitis B virus carriers in the Han Chinese population. Hepatology. 2011;53:422-428.
Mbarek H, Ochi H, Urabe Y, et al. A genome-wide association study of chronic hepatitis B identified novel risk locus in a Japanese population. Hum Mol Genet. 2011;20:3884-3892.
Nishida N, Sawai H, Matsuura K, et al. Genome-wide association study confirming association of HLA-DP with protection against chronic hepatitis B and viral clearance in Japanese and Korean. PLoS ONE. 2012;7:e39175.
Chang SW, Fann CS, Su WH, et al. A genome-wide association study on chronic HBV infection and its clinical progression in male Han-Taiwanese. PLoS ONE. 2014;9:e99724.
Zhang H, Zhai Y, Hu Z, et al. Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. Nat Genet. 2010;42:755-758.
Wang WT, Li Z, Shi M, et al. Association of the GLB1 rs4678680 genetic variant with risk of HBV-related hepatocellular carcinoma. Oncotarget. 2016;7:56501-56507.
Jiang DK, Ma XP, Wu X, et al. Genetic variations in STAT4, C2, HLA-DRB1 and HLA-DQ associated with risk of hepatitis B virus-related liver cirrhosis. Sci Rep. 2015;5:16278.
Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004;351:1206-1217.
Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352:2682-2695.
Liaw YF, Jia JD, Chan HL, et al. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology. 2011;54:1591-1599.
European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167-185.
Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1-98.
Konerman MA, Lok AS. Interferon treatment for hepatitis B. Clin Liver Dis. 2016;20:645-665.
Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399-401.
Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461:798-801.
Sonneveld MJ, Wong VW, Woltman AM, et al. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology. 2012;142:513-520. e1.
Lampertico P, Viganò M, Cheroni C, et al. IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Hepatology. 2013;57:890-896.
Wei L, Wedemeyer H, Liaw Y-F, et al. No association between IL28B genotype and response to peginterferon alfa-2a (40KD) in HBe antigen-positive and HBe antigen-negative patients with chronic hepatitis B in three large randomized clinical studies. Hepatology. 2013;58:647A-648A.
Jansen L, de Niet A, Stelma F, et al. HBsAg loss in patients treated with peginterferon alfa-2a and adefovir is associated with SLC16A9 gene variation and lower plasma carnitine levels. J Hepatol. 2014;61:730-737.
Chuang WL, Jia J, Chan HLY, et al. Responses are durable for up to 5 years after completion of peginterferon alfa-2a treatment in hepatitis B e antigen-positive patients. Aliment Pharmacol Ther. 2018;47:1306-1316.
Hsu CW, Su WW, Lee CM, et al. Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B. J Formos Med Assoc. 2018;117:588-597.
Lampertico P, Viganò M, Di Costanzo GG, et al. Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B. Gut. 2013;62:290-298.
International HapMap Consortium. The International HapMap Project. Nature. 2003;426:789-796.
International HapMap Consortium. A haplotype map of the human genome. Nature. 2005;437:1299-1320.
International HapMap Consortium, Frazer KA, Ballinger DG, et al. A second generation human haplotype map of over 3.1 million SNPs. Nature. 2007;449:851-861.
Ionita-Laza I, Lee S, Makarov V, Buxbaum JD, Lin X. Sequence kernel association tests for the combined effect of rare and common variants. Am J Hum Genet. 2013;92:841-853.
Wu MC, Lee S, Cai T, Li Y, Boehnke M, Lin X. Rare-variant association testing for sequencing data with the sequence kernel association test. Am J Hum Genet. 2011;89:82-93.
Patterson N, Price AL, Reich D. Population structure and eigenanalysis. PLoS Genet. 2006;2:e190.
Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet. 2006;38:904-909.
Gould HJ, Sutton BJ. IgE in allergy and asthma today. Nat Rev Immunol. 2008;8:205-217.
Chiu YH, Macmillan JB, Chen ZJ. RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway. Cell. 2009;138:576-591.
Tai AW, Benita Y, Peng LF, et al. A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. Cell Host Microbe. 2009;5:298-307.
Liu Y, Wang X, Li S, et al. The role of von Willebrand factor as a biomarker of tumor development in hepatitis B virus-associated human hepatocellular carcinoma: a quantitative proteomic based study. J Proteomics. 2014;106:99-112.
Tang R, Kong F, Hu L, et al. Role of hepatitis B virus X protein in regulating LIM and SH3 protein 1 (LASP-1) expression to mediate proliferation and migration of hepatoma cells. Virol J. 2012;9:163.
Liu L, Li Y, Zhang S, Yu D, Zhu M. Hepatitis B virus X protein mutant upregulates CENP-A expression in hepatoma cells. Oncol Rep. 2012;27:168-173.
Manchia M, Cullis J, Turecki G, Rouleau GA, Uher R, Alda M. The impact of phenotypic and genetic heterogeneity on results of genome wide association studies of complex diseases. PLoS ONE. 2013;8:e76295.
Buster EH, Hansen BE, Lau GK, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology. 2009;137:2002-2009.
Sonneveld MJ, Rijckborst V, Zeuzem S, et al. Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2012;56:67-75.
Wang YC, Yang SS, Su CW, et al. Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis. Sci Rep. 2016;6:29605.